Literature DB >> 32633366

LINC00460 promotes proliferation and inhibits apoptosis of non-small cell lung cancer cells through targeted regulation of miR-539.

H-X Wang1, L-J Kang, X Qin, J Xu, J-W Fei.   

Abstract

OBJECTIVE: To explore the effects of long intergenic non-coding ribonucleic acid 00460 (LINC00460) on the proliferation and apoptosis of non-small cell lung cancer (NSCLC) cells.
MATERIALS AND METHODS: In this study, the expression of LINC00460 in lung cancer tissues and its prognostic potential in NSCLC patients were analyzed using the Gene Expression Profiling Interactive Analysis (GEPIA) website and the Cancer Genome Atlas (TCGA) database. Then, the influences of silenced LINC00460 on proliferation and apoptosis in A549 cells were observed via methyl thiazolyl tetrazolium (MTT) assay, colony formation assay, and flow cytometry in vitro. Moreover, Dual-Luciferase reporter assay and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) were performed to detect the targeting relationship between LINC00460 and micro RNA (miR)-539. The biological role of the LINC00460/miR-539 axis in the proliferation of A549 cells was examined using MTT assay.
RESULTS: It was found that the expression level of LINC00460 was significantly upregulated in NSCLC tissues and cell lines, and particularly negatively correlated with the overall survival (OS). According to the in vitro experimental results, LINC00460 knockdown inhibited the proliferation of A549 cells, but promoted their apoptosis. Dual-Luciferase reporter assay results revealed that miR-539 was directly targeted by LINC00460 and involved in the LINC00460-mediated proliferation of A549 cells.
CONCLUSIONS: LINC00460 is overexpressed in NSCLC tissues and can promote the growth of NSCLC cells by targeting miR-539.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32633366     DOI: 10.26355/eurrev_202006_21663

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  Aberration of lncRNA LINC00460 is a Promising Prognosis Factor and Associated with Progression of Clear Cell Renal Cell Carcinoma.

Authors:  Shijie Zhang; Fengyun Zhang; Yingdong Niu; Shenglong Yu
Journal:  Cancer Manag Res       Date:  2021-08-16       Impact factor: 3.989

2.  LINC00460 Is a Dual Biomarker That Acts as a Predictor for Increased Prognosis in Basal-Like Breast Cancer and Potentially Regulates Immunogenic and Differentiation-Related Genes.

Authors:  Mireya Cisneros-Villanueva; Lizbett Hidalgo-Pérez; Alberto Cedro-Tanda; Mónica Peña-Luna; Marco Antonio Mancera-Rodríguez; Eduardo Hurtado-Cordova; Irene Rivera-Salgado; Alejandro Martínez-Aguirre; Silvia Jiménez-Morales; Luis Alberto Alfaro-Ruiz; Rocío Arellano-Llamas; Alberto Tenorio-Torres; Carlos Domínguez-Reyes; Felipe Villegas-Carlos; Magdalena Ríos-Romero; Alfredo Hidalgo-Miranda
Journal:  Front Oncol       Date:  2021-04-12       Impact factor: 6.244

3.  Immune-Related lncRNA Pairs as Prognostic Signature and Immune-Landscape Predictor in Lung Adenocarcinoma.

Authors:  Zhengrong Yin; Mei Zhou; Tingting Liao; Juanjuan Xu; Jinshuo Fan; Jingjing Deng; Yang Jin
Journal:  Front Oncol       Date:  2022-01-10       Impact factor: 6.244

Review 4.  LncRNA LINC00460: Function and mechanism in human cancer.

Authors:  Xi Chen; Jiwu Song; Xiaoxiao Wang; Dongyuan Sun; Yunxia Liu; Yingying Jiang
Journal:  Thorac Cancer       Date:  2021-11-25       Impact factor: 3.500

Review 5.  Interaction between Non-Coding RNAs and Androgen Receptor with an Especial Focus on Prostate Cancer.

Authors:  Mohammad Taheri; Tayyebeh Khoshbakht; Elena Jamali; Julia Kallenbach; Soudeh Ghafouri-Fard; Aria Baniahmad
Journal:  Cells       Date:  2021-11-16       Impact factor: 6.600

Review 6.  The Impact of lncRNAs and miRNAs on Apoptosis in Lung Cancer.

Authors:  Soudeh Ghafouri-Fard; Amin Aghabalazade; Hamed Shoorei; Jamal Majidpoor; Mohammad Taheri; Majid Mokhtari
Journal:  Front Oncol       Date:  2021-07-21       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.